Table 3.

Comparison of medication use among multi-system inflammatory syndrome in children cohort stratified by presence of cardiac complications.

Variable of interest	All cases (n = 39)	Cardiac complications present (n = 19)	Cardiac complications absent (n = 20)	p-value
	n (%)	n (%)	n (%)
	Any vasoactive	21 (54%)	12 (63%)		9 (45%)	0.34
Dopamine	1 (3%)	0	1 (5%)	1.00
Epinephrine	21 (54%)	12 (63%)	9 (45%)	0.34
Milrinone	10 (26%) *	8 (42%)	2 (10%)	0.03
Norepinephrine	6 (15%)	5 (26%)	1 (5%)	0.09
Immune therapy
Intravenous immunoglobulin	38 (97%)	18 (95%)**	20 (100%)	0.49
Anakinra	29 (74%)	16 (84%)	13 (65%)	0.27
Any steroid	10 (26%)	7 (37%)	3 (15%)	0.16
Dexamethasone	1 (3%)	0	1 (5%)	1.00
Hydrocortisone	9 (23%)	6 (32%)	3 (15%)	0.27
Prednisone	1 (3%)	1 (5%)	0	0.49
Any anticoagulant (enoxaparin or rivaroxaban)	35 (90%)	18 (95%)	17 (85%)	0.61
Aspirin	38 (97%)	18 (95%)	20 (100%)	0.49

^*The indication for milrinone therapy included myocardial systolic dysfunction (n = 6), shock (n = 3), and low blood pressure (n = 1).

^**One patient was diagnosed retrospectively with multi-system inflammatory syndrome.The patient presented in shock with multi-system involvement and received hydrocortisone prior to the first report of multi-system inflammatory syndrome in children in United Kingdom in April 2020. Therefore, the patient did not receive intravenous immunoglobulin (IVIG) as per our protocol. The patient had mild systolic dysfunction that resolved by time of last follow up. No coronary artery abnormality was seen.

Statistically significant differences are marked by bold rows.